PerkinElmer Inc
Uždarymo kaina
SektoriusSveikatos priežiūra
0
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
Max
Pajamos | -58M 41M |
|---|---|
Pardavimai | -61M 711M |
P/E Sektoriaus vid. | 48.341 49.712 |
Pelnas, tenkantis vienai akcijai | 1.06 |
Dividendų pajamingumas | 0.28 |
Pelno marža | 5.726 |
Darbuotojai | 11,000 |
EBITDA | -38M 180M |
Rekomendacijos | Pirkti |
|---|---|
12 mėnesių prognozė | +3.75% upside |
Dividendų pajamingumas Sektoriaus vid. | 0.28% 2.36% |
|---|---|
Kitas uždarbis | 2026-07-27 |
Kitas dividendų mokėjimo data | 2026-08-07 |
Kita Ex Dividend data | 2026-07-17 |
Rinkos kapitalizacija | 1.5B 11B |
|---|---|
Ankstesnė atidarymo kaina | 0 |
Ankstesnė uždarymo kaina | 0 |
Naujienos nuotaikos
By Acuity
28%
72%
60 / 342 reitingas Healthcare
PerkinElmer Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę PerkinElmer Inc
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.